Cancer cells harboring oncogenic BRaf mutants, but not oncogenic KRas mutants, are sensitive to MEK inhibitors (MEKi). The mechanism underlying the intrinsic resistance to MEKi in KRas-mutant cells is under intensive investigation. Here, we pursued this mechanism by live imaging of extracellular signal-regulated kinases (ERK) and mammalian target of rapamycin complex 1 (mTORC1) activities in oncogenic KRas or BRaf-mutant cancer cells. We established eight cancer cell lines expressing Förster resonance energy transfer (FRET) biosensors for ERK activity and S6K activity, which was used as a surrogate marker for mTORC1 activity. Under increasing concentrations of MEKi, ERK activity correlated linearly with the cell growth rate in BRaf-mutant cancer cells, but not KRas-mutant cancer cells. The administration of PI3K inhibitors resulted in a linear correlation between ERK activity and cell growth rate in KRas-mutant cancer cells. Intriguingly, mTORC1 activity was correlated linearly with the cell growth rate in both BRaf-mutant cancer cells and KRas-mutant cancer cells. These observations suggested that mTORC1 activity had a pivotal role in cell growth and that the mTORC1 activity was maintained primarily by the ERK pathway in BRaf-mutant cancer cells and by both the ERK and PI3K pathways in KRas-mutant cancer cells. FRET imaging revealed that MEKi inhibited mTORC1 activity with slow kinetics, implying transcriptional control of mTORC1 activity by ERK. In agreement with this observation, MEKi induced the expression of negative regulators of mTORC1, including TSC1, TSC2 and Deptor, which occurred more significantly in BRaf-mutant cells than in KRas-mutant cells. These findings suggested that the suppression of mTORC1 activity and induction of negative regulators of mTORC1 in cancer cells treated for at least 1 day could be used as surrogate markers for the MEKi sensitivity of cancer cells.
INTRODUCTION
The Ras-Raf-MEK-ERK signaling pathway has a central role in cell proliferation, differentiation and survival. 1 Gain-of-function mutations in the Ras-Raf-MEK-ERK pathway have frequently been observed in various cancers, including melanoma, pancreatic cancer, lung cancer, colorectal cancer and breast cancer. 2 These mutations induce hyperactivation of the pathway, culminating in the induction of cancers.
The growth of many cancer cells depends on a specific driving oncogene, a phenomenon known as 'oncogene addiction'. 3, 4 This idea has been well-established in BCR-ABL-induced chronic myelogenous leukemias and epidermal growth factor receptor (EGFR) mutant non-small lung cancer. 5 Therefore, targeting molecules in the Ras-Raf-MEK-ERK pathway could be a promising therapeutic strategy. MEK inhibitors (MEKi) have been tested in early-phase clinical trials as BRaf inhibitors. 6 Cancer cells harboring BRaf mutation undergo G1 cell cycle arrest and apoptosis by BRaf inhibitors and MEKi treatment, 7 clearly indicating that BRafmutant cancer cells are 'addicted' to the extracellular signalregulated kinase (ERK) pathway. Several cancer cell lines harboring active KRas mutations also exhibit oncogene addiction, which is manifested by the induction of cell cycle arrest and apoptosis by silencing of KRas expression. 8 Unlike BRaf-mutant cancer cells, Rasmutant cancer cells are less sensitive to MEKi. 7 In Ras-mutant cells, MEKi demonstrates a cytostatic effect rather than cytotoxic activity. 6 Resistance to targeted drugs has emerged as a critical issue in the clinical outcome of anticancer therapy. There exist two mechanisms by which cancer cells demonstrate resistance to targeted drugs: an intrinsic and an acquired mechanism. 9 Intrinsic resistance is caused by genetic and/or epigenetic alterations existing before treatment. On the other hand, acquired resistance is induced by drug treatment over a long period, and it can be due to gene mutation, overexpression or silencing acquired after treatment. The low sensitivity to MEKi in the Ras-mutant cancer cells is an example of intrinsic resistance. One of the possible mechanisms by which oncogenic Ras mutants, but not oncogenic BRaf mutants, render cancer cells resistant to MEKi is the presence of feedback loops and cross-talk between Ras and other pathways, such as the EGFR pathway and the PI3K-Akt-mTOR pathway. 6, [10] [11] [12] For example, it has been reported that inhibition of ERK by MEKi releases negative feedback from ERK to CRaf, thereby increasing phosphorylated MEK and decreasing drug efficacy. 13, 14 Intriguingly, the BRaf V600E mutant disrupts the negative feedback from ERK to CRaf.
14 In addition, cross-talk between the Ras-ERK and PI3K-Akt-mTOR pathways is involved in the intrinsic resistance. Indeed, MEKi treatment causes Akt phosphorylation, which determines the susceptibility of cancer cells to MEK inhibition. 10, 15 To overcome MEKi resistance in KRas-mutant cancer cells, the logical approach would be a combination strategies using MEKi to induce cytotoxicity. One of the promising combinations is MEKi plus PI3K/mTOR or Akt inhibitors, 16, 17 and these clinical trials are ongoing, 6 although toxicity of both inhibitors limits the maximally tolerated doses that can be used in combination. 18, 19 However, it is unclear to what extent KRas-mutant cancer cells are addicted to either the Ras-ERK pathway or the PI3K-Akt-mTOR pathway, or what roles feedback and cross-talk have in the process of intrinsic resistance in these cells.
Here, we have addressed this issue by monitoring the effects of MEKi on ERK and mammalian target of rapamycin complex 1 (mTORC1) activities and cell growth with live-cell imaging in BRafor KRas-mutant cancer cells. We found that MEKi-induced suppression of ERK activity was linearly correlated with the reduction of mTORC1 activity and cell growth rate in BRaf-mutant cancer cells, but not in KRas-mutant cells. The MEKi-induced suppression of mTORC1 activity was markedly slower than the ERK suppression. In agreement with this finding, we found that several genes involved in the regulation of mTORC1 activity were transcriptionally regulated.
RESULTS
Linear correlation between ERK activity and cell growth rate upon MEKi treatment in BRaf-mutant cells but not in KRas-mutant cells To address the mechanisms of MEKi resistance in cancer cells, we designed a live-cell imaging platform by which the molecular activity and cell growth rate in cancer cells could be simultaneously monitored in the presence of various inhibitors ( Figures  1a and b) . For the analysis, we chose six cell lines that harbor oncogenic mutations of BRaf or KRas, and two cell lines that are not known to have any oncogenic mutations of BRaf and KRas (Supplementary Table 1 ). The cell lines were stably expressed with a Förster resonance energy transfer (FRET) biosensor for ERK activity, EKAREV-nls or for S6K activity, Eevee-S6K. 20 After the addition of inhibitor, cells were monitored for the kinase activity and cell number every day (Figure 1b) .
First, we examined the dose effect of AZD6244, a potent MEKi, on the ERK activity and growth rate of HT-29 cells bearing the V600E BRaf mutation and HCT116 cells bearing the G13D KRas. HT-29 cells exhibited almost identical IC50 values for both ERK activity (0.030 ± 0.0045 μM) and cell growth rate (0.064 ± 0.024 μM) (Figure 1c ), resulting in a linear correlation between ERK activity and cell growth rate (Figure 1d ). On the other hand, in HCT116 cells the IC50 of 1.2 ± 0.32 μM for the cell growth rate was~50-fold higher than the IC50 of 0.023 ± 0.0034 μM for ERK activity, resulting in a nonlinear correlation between ERK activity and growth rate ( Figures  1e and f) . The resistance of HCT116 to MEKi was as reported by Friday et al. 21 Importantly, a linear correlation between ERK activity and cell growth rate was observed in all three BRaf-mutant cell lines but not in the KRas-mutant cell lines (Figure 1g ). ERK activity in KRasmutant cells was slightly restored 1 day after MEKi treatment (Supplementary Figure S1) . In cell lines without known mutation of BRaf or KRas, no clear tendency could be identified (Figure 1g ). Taken together, these results showed that the cell growth rate was entirely dependent on ERK activity in BRaf-mutant cells, but not in KRasmutant cells. There are several possible explanations for the inhibition of the cell growth of KRas-mutant cells by a high dose of MEKi-for example, very low ERK activity may have been sufficient to maintain the cell growth of KRas-mutant cells, or alternatively, the ERK activity may have been dispensable, but other kinases that are indispensable for cell growth could have been inhibited at high concentrations of MEKi. In any event, the use of high-dose MEKi as a therapeutic is clinically impractical if we take the adverse effects of MEKi into account. 22 Dependence of cell growth on the PI3K-Akt-mTOR pathway If ERK is dispensable for the cell growth of KRas-mutant cells, does the PI3K-Akt-mTOR pathway support the proliferation of these cells? To answer this question, we examined the effect of inhibitors against EGFR, BRaf, MEK, RSK, PI3K and mTOR on cell growth (Figure 2a) . To compare the sensitivity among eight cell lines, we used a relative resistance index, which we calculated by dividing the IC50 value for a given inhibitor in each cell line by the lowest IC50 value for that inhibitor among all eight cell lines (Figure 2b ). The sensitivity of the cell lines was analyzed by clustering ( Figure 2c ). As expected, the cell lines were clustered into two groups, the BRaf-mutant cell lines and the others. The BRaf-mutant cell lines were more sensitive to BRaf inhibitors/MEKi than the KRasmutant cell lines or KRas and BRaf WT cell lines (Figure 2c ). On the other hand, the BRaf-mutant cell lines were more resistant to the PI3K inhibitor and mTOR inhibitor than the KRas-mutant cell lines and KRas and BRaf WT cell lines, suggesting that the MEKi-resistant cell lines were more dependent on PI3K-Akt-mTOR signaling for cell growth than were the BRaf-mutant cell lines. Therefore, if the PI3K-Akt-mTOR pathway was abrogated, would the KRas-mutant cell lines exhibit linear correlation of ERK activity with cell growth rate, as was the case in BRaf-mutant cell lines? To answer this question, we examined the correlation between the ERK activity and cell growth rate of BRaf-mutant HT-29 cells and KRas-mutant HCT116 cells in the presence of increasing concentrations of MEKi and PI3K inhibitor (PI3Ki) (Figures 2d and g ). HT-29 cells demonstrated the linear correlation between ERK activity and cell proliferation rate regardless of the treatment of PI-103, a PI3Ki (Figure 2e ). To the contrary, PI-103 treatment sensitized HCT116 cells to MEKi; the cell growth rate was linearly correlated with ERK activity in the presence of 1 μM PI-103 (Figure 2g , light-green dots). We further analyzed ERK activity distribution at the single-cell level in HT-29 and HCT116 cells (Supplementary Figure S2) . ERK activity followed normal bellshape distribution, and gradually decreased by MEK inhibition with the bell-shape distribution keeping in both HT-29 cells and HCT116 cells. These results strongly suggested that the signals from the Raf-MEK-ERK pathway and PI3K-Akt-mTOR pathway converged on a molecule that controls the cell growth of HCT116 cells, and probably also the other KRas-mutant or BRaf-mutant cancer cells.
Linear correlation between S6K activity and cell growth rate in both BRaf-and KRas-mutant cells We assumed that mTORC1 was a key cell growth controller functioning downstream of ERK and PI3K. To examine the correlation of mTORC1 activity with the cell growth rate, we established cell lines expressing the S6K FRET biosensor, Eevee-S6K, which was used as a surrogate marker for mTORC1 activity. The S6K activity was decreased in a manner dependent on cell density in both HT-29 and HCT116 cells (Figures 3a and d) . In HT-29 cells, MEKi slowly suppressed S6K activity in a dosedependent manner from 1 day after treatment (Figure 3a) . In contrast, PI-103 treatment decreased S6K activity within 20 min, but the effect was canceled in 1-2 days (Figure 3b ). These observations suggested that ERK regulates mTORC1 in a transcription-dependent manner, and that the same mechanism may operate to cancel the PI3Ki-induced decrease of S6K activity in HT-29 cells. HCT116 cells showed higher basal S6K activity than HT-29 cells, and also showed slow inhibition of S6K activity by MEKi from 1 day after treatment as observed in HT-29 cells (Figure 3c ). The effect of PI3Ki on S6K was rapid and sustained in HCT116 cells (Figure 3d (Figures 4g and l) . Therefore, a rapamycininsensitive target of mTORC1, but not S6K, had a critical role in cell growth. 23 A candidate molecule would be 4E-BP1. 24 To examine whether this molecule was in fact the target of mTORC1, we used a tetracycline-inducible expression of dominant-negative mutant of 4E-BP1, 4E-BP1 4A, for the inhibition of 4E-BP1 function. The expression of the dominant-negative mutant of 4E-BP1 clearly suppressed the proliferation of A375, HT-29 and HCT116 cells (Figure 4m ). These results indicated that mTORC1-activated 4E-BP1 was required for cell growth in both MEKi-sensitive and -resistant cells. Therefore, the different sensitivity to MEKi between BRaf-mutant and KRas-mutant cells was attributed to the mechanisms by which ERK activity regulated mTORC1 activity.
MEKi treatment induced global change in gene expression in mTORC1 pathway components How does the Raf-MEK-ERK pathway regulate mTORC1? Although the post-translational mechanisms could be considered such as negative feedbacks and cross-talk between ERK and mTORC1 pathway (see Discussion), the slow inhibition of mTORC1/S6K activity by MEKi (Figures 3a and c) prompted us to examine the transcriptional/translational regulation of mTORC1 by ERK. To test this hypothesis, the gene expression profile was compared between cells cultured in the presence and absence of a MEKi, PD0325901 (Figure 5a ). We identified 8428 and 7786 genes in HT-29 cells and HCT116 cells, respectively, as differentially expressed genes (DEGs) (Figures 5b and c) . Among them, we focused on genes that are related to mTORC1 signaling. Upon MEKi treatment, three out of nine positive regulators for the mTORC1 signaling pathway were downregulated, that is, Akt1, Rheb and Raptor, whereas four out of five negative regulators were upregulated, that is, TSC1, TSC2, DEPTOR and REDD1 (Figure 5d ). Of note, these down-and upregulated mTORC1-related genes were more evident in HT-29 cells than in HCT116 cells. To check whether the change in gene expression pattern was also observed in other cell lines, the expression levels of these genes were quantified by quantitative PCR. We found that the upregulation of TSC2 and DEPTOR genes was more significant in BRaf-mutant cells than in KRas-mutant cells (Figure 5e ). We speculated that the upregulation of TSC2 and DEPTOR would be a mechanism for mTORC1 inactivation by MEKi. However, the depletion of TSC2 or DEPTOR by RNA interference did not affect S6K activity or cell growth in the presence of MEKi in BRaf-mutant cells (Supplementary Figure S6 and S7) . The knockdown of either TSC2 or DEPTOR might be insufficient to rescue MEKi-induced mTORC1 inactivation. Taken together, these results lead us to suggest that ERK inactivation upon MEKi treatment induces the global change in gene expressions related to mTORC1 signaling, and the alteration of these genes cooperatively results in the mTORC1 inactivation and cell growth inhibition.
DISCUSSION
On the basis of the results of the present experiments, we propose that the following mechanism underlies the difference of MEKi sensitivity between BRaf-and KRas-mutant cancer cells (Figure 6 ). In both BRaf-and KRas-mutant cancer cells, mTORC1 activity is a bottleneck for cell proliferation and survival. In BRaf-mutant cancer cells, mTORC1 activity is regulated primarily by ERK activity, which is inferred from the linear correlation of ERK activity with mTORC1 activity in the presence of various concentrations of MEKi (Figure 6a ). By contrast, KRas-mutant cancer cells use both ERK and PI3K-Akt pathways to maintain mTORC1 activity, and therefore MEKi monotherapy cannot significantly reduce the mTORC1 activity and cell growth (Figure 6b ). This could be due to KRas activation of the PI3K-Akt-mTORC1 pathway through the direct binding of KRas to p110 catalytic subunits of PI3K. 25 In the cell lines used in the present research, neither the presence of PI3K mutation nor the presence of PTEN mutation was correlated with the sensitivity to PI3Ki and mTORC1/2 inhibitor (Figure 2c and Supplementary Table S1 ). Intriguingly, the drug sensitivities of Ras WT and BRaf WT cancer cells were found to be equivalent to those of KRas-mutant cancer cells by clustering (Figure 2c ). The data implicate that oncogenic BRaf mutation reduces PI3K-Akt dependency and subsequently increases ERK dependency on mTORC1 activity.
Our data suggest that mTORC1 activity is transcriptionally regulated by ERK. The Ras-ERK pathway activates the PI3K-AktmTORC1 pathway by multiple mechanisms. 26 It has been shown that ERK and RSK, a downstream molecule of ERK, phosphorylate and inactivate TSC2, a component of Rheb GAP, leading to the activation of Rheb and mTORC1. 27 A similar mechanism has been proposed for Raptor; ERK and RSK phosphorylate Raptor and promote tumorigenesis through 4E-BP phosphorylation. 28 However, the ERK and/or RSKmediated phosphorylation of the regulators of mTORC1 does not seem to have a major role in maintaining the mTORC1 activity of the cell lines used in the present study, because we found that MEKi decreased mTORC1 activity with slow kinetics, requiring nearly 1 day of treatment for full suppression (Figures  3a and c) . It should be noted that the observed slow kinetics was not due to the kinetics of the FRET biosensor, which could capture the fast mTORC1 inactivation by PI3Ki or rapamycin (Figures 3b and d) . 20 In support of our proposal, we observed Other possible mechanisms that could have contributed to the difference of MEKi sensitivity between BRaf-and Ras-mutant cells are: (1) the negative feedback from ERK to Raf, which is abrogated in BRaf-mutant cells, 13, 14, 21 and (2) the negative feedback from ERK to EGFR. 11, 12 As for the negative feedback from ERK to Raf, we observed a slight restoration of ERK activity in KRas-mutant cells 1 day after MEKi treatment (Supplementary Figure S1) . However, the increase in IC50 values of ERK activity was approximately twofold, which was unlikely to explain the~50-fold difference in the IC50 values for cell growth (Figure 1e ). These data were essentially consistent with the previous study. 21 As for the negative feedback from ERK to EGFR, unlike in the previous reports, 11, 12 we could not reproduce MEKi-induced activation of Akt in our experimental condition, namely in the presence of 10% serum condition (Supplementary Figure S8) . Consistent with this result, no decrease of cell growth rate and S6K activity was observed by the additional treatment of an EGFR inhibitor, Gefitinib (Supplementary Figure S9) . We confirmed that the concentration of Gefitinib used in the analyses was sufficient to suppress EGFR activation (Supplementary Figure S10) . These results supported our claim that ERK regulates mTORC1 activity through transcriptional mechanisms, though we have not yet obtained direct experimental evidences.
An important message from this study is that the sensitivity of mTORC1 to MEKi could be used as a promising surrogate marker of cancer cells for MEKi sensitivity. In this study, as an indicator of mTORC1 activity we used S6K-mediated phosphorylation of Rictor at Thr1135, which was detected either by the FRET biosensor Eevee-S6K 20 or anti-phospho-Rictor (Thr1135) antibody. In line with this view, phospho-S6 (Ser240/S244) and phospho-S6 (Ser235/S236) have been used as markers of resistance to MEKi in melanoma cells. 29 Importantly, the suppression of mTORC1 activity was observed only at 1 day after MEKi treatment, when the mRNAs of TSC2 and DEPTOR were increased. Therefore, by measuring the S6K activity or expression levels of TSC2 and DEPTOR in patient samples pretreated with MEKi for 1 day, we may be able to predict the sensitivity of cancer cells to MEKi.
MATERIALS AND METHODS

Cell culture
The cell lines HCT116, A549, NCI-H460 and MCF10A were obtained from American Type Culture Collection. The cell lines HT-29, A375 and LIM1215 were obtained from European Collection of Cell Cultures. HEK-293 T cells were purchased from Clontech (Mountain View, CA, USA). Colo205 cells were the kind gift of Dr Won Do Heo (KAIST, Korea). A549, A375 and HEK-293T cells were maintained in Dulbecco's Modified Eagle's medium (Sigma-Aldrich, St Louis, MO, USA). HCT116 and HT-29 cells were grown in McCoy's 5A medium (Sigma-Aldrich). NCI-H460 and Colo205 cells were cultured in RPMI1640 (Sigma-Aldrich). LIM1215 cells were maintained in DMEM/F12 (Sigma-Aldrich). The growth media described above were supplemented with 10% fetal bovine serum (FBS) and penicillin/ streptomycin. MCF10A cells were grown in mammary epithelial basal medium (Cell Applications Inc., San Diego, CA, USA) supplemented with the growth supplements (Cell Applications Inc.) and 100 ng/ml cholera toxin (BioAcademia, Tokyo, Japan). All cells were incubated in a humidified atmosphere of 5% CO 2 at 37˚C.
Plasmids and establishment of stable cell lines
FRET biosensors for ERK activity with a nuclear localization signal, EKAREV-nls and for S6K activity with a nuclear exporting signal, Eevee-S6K, were described previously. 20 Complementary DNAs of EKAREV-nls or Eevee-S6K were subcloned into pPBbrs vector, a PiggyBac transposon vector 30 with IRES-bsr (blasticidin S resistant gene), pT2Apuro vector, a Tol2 transposon vector 31 with IRES-pac (puromycin resistant gene), or pCSIIbsr-EF, a lentivirus vector 32 with IRES-bsr. mCherry tagged with tandem repeats of nuclear localization signal, mCherry-NLSx2, was introduced into the pCX4neo retrovirus vector. 33 pCW57.1-4E-BP1 4xAla and lentiCRISPR v2 were obtained from Addgene (plasmid 38240 and plasmid 52961, respectively).
To establish stable cell lines expressing FRET biosensors by a transposon system, cells were co-transfected with pPB vector and pCMV-mPBase, which was obtained from the Wellcome Trust Sanger Institute, or with pT2A vector and pCAGGS-T2TP, which was a kind gift from Dr Kawakami (National Institute for Genetics, Japan). One day after transfection, the transfected cells were selected with 20 μg/ml of blasticidin S or 2 μg/ml puromycin, and then left for at least 1 week. For lentivirus-mediated introduction of the FRET biosensor gene, a complementary DNA encoding YPet, a yellow fluorescent protein variant, was codon-diversified to prevent recombination between the yellow fluorescent protein and cyan fluorescent protein (CFP) genes of the biosensor (Aoki, unpublished) . For lentiviral production, HEK-293 T cells were co-transfected with the pCSII-EF vector, psPAX2 from Addgene plasmid 12260 and pCMV-VSV-G-RSV-Rev, which was a kind gift from Dr Miyoshi (RIKEN) by using Polyethyleneimine 'Max' MW 40 000 (Polyscience Inc., Warrington, PA, USA). For retrovirus, pGP was used instead of psPAX2. Virus-containing media were collected at 48 h after transfection, filtered and used to infect target cells. Two days after infection, the infected cells were selected with 20 μg/ml blasticidin S. Cell lines expressing Eevee-S6K were additionally infected with retrovirus encoding mCherry-NLSx2 protein and selected with 1 mg/ml G418. Bulk of infected cells was used for imaging.
Reagents
Gefitinib, SB-590885, AZD6244 and BI-D1870 were purchased from Symansis (Shanghai, China). PI-103 and PD153035 were purchased from Calbiochem (La Jolla, CA, USA). Torin1 was purchased from Tocris Bioscience (Ellisville, MO, USA). Rapamycin was purchased from LC Laboratories (Woburn, MA). PD0325901 was purchased from Wako (Osaka, Japan). Doxycyclin was obtained from LKT Laboratories (St Paul, MN, USA). Epidermal growth factor was purchased from Sigma-Aldrich.
Gene silencing using siRNAs 
Raptor knockout using CRISPR/Cas9
For CRISPR/Cas9-mediated knockout of RPTOR gene, single guide RNAs targeting RPTOR were designed using CRISPR Design Tools (http://crispr. mit.edu/). Targeting sequences are just after the start codon (no. 1) or region encoding 1191 RVYDRR 1196 (no. 2 and no. 3) of RPTOR, which is required for the interaction with mTOR. 34 Oligo DNAs for the single guide RNAs were annealed and inserted into lentiCRISPR v2 vector digested with BsmBI restriction enzyme. Single guide RNAs-Cas9 cassettes were introduced to HT-29 cells by lentivirus-mediated gene transfer. Infected cells were selected by 2 μg/ml Puromycin for at least 2 weeks and obtained bulk cell lines were analyzed.
Multiwell FRET imaging
FRET images were obtained and processed using essentially the same conditions and procedures as previously reported. 35 In brief, the bottoms of 96-well glass-based plates (Asahi Techno Glass, Tokyo, Japan) were coated with collagen type I (Nitta Gelatin Inc., Osaka, Japan) before plating cells. Cells expressing EKAREV-nls or Eevee-S6K/mCherry-NLSx2 were plated on the collagen-coated 96-well plate at a cell density of 3000-4000 cells/well. After cells attached to the glass base, the media was exchanged for 300 μl of imaging medium comprised of Medium 199 (Sigma-Aldrich) with 20 mM HEPES, 10% fetal bovine serum and penicillin/ streptomycin. Blasticidin S or/and puromycin were added to the imaging medium if necessary. Cells in the 96-well plates were cultured in CO2 incubators, and applied to a fluorescence microscope at the time point of image acquisition. All images were acquired with an inverted microscope (IX81; Olympus, Tokyo, Japan) equipped with a cooled charge-coupled device camera (Cool SNAP-K4; Roper Scientific, Tucson, AZ, USA), illumination systems (Spectra-X light engine; Lumencore, OR or CoolLED precisExcite; Molecular Devices, Sunnyvale, CA, USA), an IX2-ZDC2 laserbased autofocusing system (Olympus), a MAC5000 controller for filter wheels and XY stage (Ludl Electronic Products, Hawthorne, NY, USA), a chamlide WP stage incubator system (Live Cell Instrument, Seoul, Korea) and a GM-4000 CO2 supplier (Tokai-Hit, Fujinomiya, Japan). The following filters used for the dual-emission imaging studies were obtained from Omega Optical (Brattleboro, VT, USA): an XF1071 (440AF21) excitation filter, an XF2034 (455DRLP) dichroic mirror, and two emission filters (XF3075 (480AF30) for CFP and XF3079 (535AF26) for yellow fluorescent protein). Cells were imaged with an UPlanSApo x20 dry objective lens (Olympus). The same four positions were acquired in each well in the time course experiments. The microscope was controlled by Metamorph software (Universal Imaging, West Chester, PA, USA).
Image analysis
For background subtraction, all images were processed by the Flatten Background function included in the Metamorph software package. The background value was determined by Otsu's method and subtracted from the images. 36 After background subtraction, FRET/CFP ratio images were created to represent the FRET efficiency. Custom-made MATLAB program was used for subsequent image analyses as previously described. 37 In brief, for the ERK FRET biosensor, EKAREV-nls, a fluorescence signal from the nucleus, was used for the segmentation of each cell. For Eevee-S6K, fluorescence from mCherry-NLSx2 was used for the segmentation of each cell. The intensities of both the FRET and CFP channels from each single cell were measured to calculate the FRET/CFP ratio. Finally, the number of segmented areas was counted as the number of cells in each well. Metamorph software and MATLAB (version R2012a; Mathworks Inc., Natick, MA, USA) were used for all of these image processing.
Western blotting and antibodies
Cells were plated on collagen-coated 12-well plates, and 1 day after plating, the cells were treated with inhibitors for 20 min or 1 day. Cells were then washed twice with cold phosphate-buffered saline and lysed with lysis buffer containing 1% NP-40. 38 After centrifugation, the supernatants were analyzed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis, followed by western blotting. The primary antibodies were as follows: p-ERK1/2(T202/Y204), ERK1/2, p-Akt(S473), pan-Akt, p-Rictor (T1135), TSC2, p-4E-BP1(T37/46), p-S6(S235/236) and S6 (Cell Signaling Technology, Beverly, MA, USA). Raptor clone 1H6.2 was from MERCK/ Millipore (Bedford, MA, USA). Rictor (mAb, 1G11) was from Enzo Life Sciences (Farmingdale, NY, USA). p-EGFR (Y1068) was from GenWay Biotech Inc. (San Diego, CA, USA). EGFR from BD Biosciences (San Jose, CA). The secondary antibodies were as follows: IRDye680LT-and IRDye800-conjugated anti-rabbit and anti-mouse IgG secondary antibodies, respectively (LI-COR Bioscience, Lincoln, NE). LI-COR blocking buffer (LI-COR Bioscience) was used to block the membranes and to dilute antibodies. Fluorescent signals were detected by an Odyssey Infrared Imager (LI-COR Bioscience).
RNA isolation and quantitative PCR
Cells were seeded onto collagen-coated six-well culture plates at a density of 1 × 10 5 cells/well and cultured overnight. The cells were treated with 0.1% dimethyl sulfoxide or 0.1 μM PD0325901 for 1 day, and were washed with ice-cold phosphate-buffered saline. Total RNAs were extracted using an RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Complementary DNA was prepared using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) with random hexamer primers according to the manufacturer's instructions. The relative abundance of transcripts was measured by quantitative PCR using SYBR Green PCR mix (Applied Biosystems). The mRNA levels for each gene were normalized to that of GAPDH. The primers used were as follows. hRheb: forward 5′-ggaatcttctgct aaagaaaatcag-3′, reverse 5′-gcatgaagacttgccttgtg-3′; hTSC2: forward 5′-cggatgcctacagcaggt-3′, reverse 5′-agacgactcgctcgatgg-3′; hDEPTOR: forward 5′-tgagaggacagaggctatatgaaa-3′, reverse 5′-tgaaggtgcgctcatacttg-3′; hGAPDH: forward 5′-gagtccactggcgtcttcac-3′, reverse 5′-gttcacacccatgacga aca-3′.
RNA sequencing and sequence analysis
Total RNAs from cells treated with dimethyl sulfoxide or PD0325901 were isolated by the method shown above. The library preparation and RNA Transcriptional control of mTORC1 activity by ERK N Komatsu et al sequencing were performed as previously described. 39 The CLC Genomics Workbench (www.clcbio.com) was used to map the reads, calculate the expression levels and determine the statistical significance of the results. Sequence reads of each data set were aligned to the human genome (Ensembl GRCh37.p13, Sep. 2013, version 75.37). The reads per kilobase (kb) of exon model per million mapped reads (RPKM) method was used to calculate the gene expression. 40 Differentially expressed genes were identified by the RNA-Seq Analysis function included in the CLC GWB platform. The false-discovery rate controlling approach was adopted to examine the significance of the differences in gene expression. The cutoff value for differentially expressed genes was false-discovery rateo 0.01.
